Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency
NCT02722304Phase 3Terminated
- Sponsor
- Takeda
- Start
- Nov 2016
- Primary completion
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of alpha1-proteinase inhibitor, alpha-1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD), chronic obstructive pulmonary disease (COPD), sponsored by Takeda. Started Nov 2016; status: terminated.
02
Drugs
alpha1-proteinase inhibitoralpha-1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02722304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02722304.